Cengild Medical Berhad Net Assets
Cengild Medical Berhad net assets. Based on the latest financial reports, Cengild Medical Berhad (0243) has net assets worth RM120.02 Million MYR (≈ $30.13 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (RM224.00 Million ≈ $56.24 Million USD) and total liabilities (RM103.97 Million ≈ $26.10 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Cengild Medical Berhad (0243) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | RM120.02 Million |
| % of Total Assets | 53.58% |
| Annual Growth Rate | 51.87% |
| 5-Year Change | 29.13% |
| 10-Year Change | N/A |
| Growth Volatility | 209.51 |
Net Assets of Cengild Medical Berhad (2020–2026)
Net assets of Cengild Medical Berhad from 2020 to 2026. This chart illustrates how Cengild Medical Berhad's net assets have evolved over time, based on quarterly financial data. See how leveraged is Cengild Medical Berhad's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for Cengild Medical Berhad (2020–2026)
The table below shows the annual net assets of Cengild Medical Berhad from 2020 to 2026. For live market cap and overall valuation, see Cengild Medical Berhad market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2026-06-30 | RM120.02 Million ≈ $30.13 Million |
+4.87% |
| 2025-06-30 | RM114.46 Million ≈ $28.74 Million |
+2.84% |
| 2024-06-30 | RM111.30 Million ≈ $27.94 Million |
+4.89% |
| 2023-06-30 | RM106.11 Million ≈ $26.64 Million |
+14.16% |
| 2022-06-30 | RM92.95 Million ≈ $23.34 Million |
+574.59% |
| 2021-06-30 | RM13.78 Million ≈ $3.46 Million |
+40.77% |
| 2020-06-30 | RM9.79 Million ≈ $2.46 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cengild Medical Berhad's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3284160700.0% over the analyzed period, indicating profitable operations and earnings retention.
Cengild Medical Berhad Net Assets Breakdown (June 2026)
Cengild Medical Berhad net assets breakdown by equity component as of June 2026.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | RM30.13 Million | 25.10% |
| Other Components | RM89.89 Million | 74.90% |
| Total Equity | RM120.02 Million | 100.00% |
Cengild Medical Berhad Competitors by Market Cap
The table below lists competitors of Cengild Medical Berhad ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ai-Media Technologies Ltd
AU:AIM
|
$33.48 Million |
|
Atlantaa Limited
NSE:ATLANTAA
|
$33.54 Million |
|
Kishin Corporation
KO:092440
|
$33.56 Million |
|
Wellbiotec Co. Ltd.
KO:010600
|
$33.58 Million |
|
Tracxn Technologies Limited
NSE:TRACXN
|
$33.46 Million |
|
Adveritas Ltd
AU:AV1
|
$33.44 Million |
|
Willowglen MSC Bhd
KLSE:0008
|
$33.44 Million |
|
Kartal Yenilenebilir Enerji Uretim AS
IS:KARYE
|
$33.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cengild Medical Berhad's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 114,455,348 to 120,024,000, a change of 5,568,652 (4.9%).
- Net income of 11,440,000 contributed positively to equity growth.
- Dividend payments of 5,830,000 reduced retained earnings.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | RM11.44 Million | +9.53% |
| Dividends Paid | RM5.83 Million | -4.86% |
| Other Changes | RM-41.35K | -0.03% |
| Total Change | RM- | 4.87% |
Book Value vs Market Value Analysis
This analysis compares Cengild Medical Berhad's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.11x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 13.38x to 1.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-06-30 | RM0.01 | RM0.16 | x |
| 2021-06-30 | RM0.02 | RM0.16 | x |
| 2022-06-30 | RM0.11 | RM0.16 | x |
| 2023-06-30 | RM0.13 | RM0.16 | x |
| 2024-06-30 | RM0.13 | RM0.16 | x |
| 2025-06-30 | RM0.14 | RM0.16 | x |
| 2026-06-30 | RM0.14 | RM0.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cengild Medical Berhad utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.53%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.63%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.87x
- Recent ROE (9.53%) is below the historical average (23.54%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 40.37% | 10.09% | 0.83x | 4.81x | RM2.97 Million |
| 2021 | 72.61% | 15.76% | 1.38x | 3.34x | RM8.63 Million |
| 2022 | 10.10% | 14.57% | 0.54x | 1.29x | RM96.04K |
| 2023 | 12.52% | 18.91% | 0.53x | 1.24x | RM2.68 Million |
| 2024 | 9.95% | 16.58% | 0.50x | 1.19x | RM-51.92K |
| 2025 | 9.66% | 13.82% | 0.44x | 1.58x | RM-389.53K |
| 2026 | 9.53% | 15.63% | 0.33x | 1.87x | RM-562.40K |
Industry Comparison
This section compares Cengild Medical Berhad's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $4,845,213,418
- Average return on equity (ROE) among peers: 17.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cengild Medical Berhad (0243) | RM120.02 Million | 40.37% | 0.87x | $33.46 Million |
| TMC Life Sciences Bhd (0101) | $762.24 Million | 2.74% | 0.11x | $183.68 Million |
| Optimax Holdings Sdn Bhd (0222) | $57.74 Million | 21.30% | 0.60x | $67.52 Million |
| DC HEALTHCARE HOLDINGS BERHAD (0283) | $15.05 Million | 63.52% | 2.21x | $18.76 Million |
| ALPHA (0303) | $28.36 Million | 8.70% | 1.64x | $335.40 Million |
| IHH Healthcare Bhd (5225) | $27.04 Billion | 0.74% | 0.65x | $17.41 Billion |
| KPJ Healthcare Bhd (5878) | $1.17 Billion | 8.79% | 1.42x | $2.93 Billion |
About Cengild Medical Berhad
Cengild Medical Berhad, an investment holding company, operates a medical center in Malaysia. The company offers various care and treatment consultant services for gastrointestinal and liver diseases, morbid obesity, and oncology and urological conditions; general cardiology and gynecology assessment; gastroenterology and hepatology; anesthesiology, general surgery, internal medicine, and radiolo… Read more